Summary:
NeoGenomics, Inc. has acquired Pathline, LLC to strengthen its commercial presence in the Northeast U.S., expanding its oncology testing services and accelerating growth in molecular and hematology-oncology testing.

Key Takeaways:

  1. Expanded Regional Presence – The acquisition establishes NeoGenomics’ footprint in the Northeast, a historically underpenetrated but rapidly growing market.
  2. Enhanced Service Capabilities – Pathline brings a comprehensive suite of pathology services, including molecular and hematology-oncology testing.
  3. Growth and Cost Synergies – NeoGenomics anticipates increased revenue and cost efficiencies, with AEBITDA benefits expected starting in 2026.

NeoGenomics, Inc., a provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics’ commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country.

NeoGenomics Builds Commercial Presence in the Northeast

Founded in 2009, Pathline serves a long-standing client base of hospitals, cancer centers, and physician practices, with approximately 98% of its revenue coming from customers in the Northeast. It offers a comprehensive suite of subspecialty pathology services, including histopathology, immunohistochemistry, cytology, cytogenetics, flow cytometry, fluorescence in situ hybridization (FISH), and molecular pathology.

“The acquisition of Pathline presents a strategic opportunity because it brings New York State (NYS) approvals and when combined with our rapid turnaround times and leading customer experience will enable us to accelerate growth to what has historically been an underpenetrated region,” says Warren Stone, chief commercial officer at NeoGenomics. “We have deeper penetration rates in areas where we have close proximity to a lab like California, Florida and Texas. Integrating Pathline’s operations into NeoGenomics’ national network will further enhance our ability to support oncologists, healthcare institutions and patients in the Northeast region.”

Growing Topline Revenue

Leveraging its differentiated commercial infrastructure, NeoGenomics expects to grow incremental topline revenue with contributions from the acquired business while operational consolidation efforts and synergies are expected to yield substantial annual cost reductions, which will be accretive to AEBITDA starting in 2026.

“As part of NeoGenomics, we are excited to leverage our expertise and strong oncology testing capabilities to reach more patients and healthcare providers,” says Zach Liu, MD, chief medical officer and laboratory director at Pathline. “Our team has built a trusted laboratory serving hospitals and oncology practices across the Northeast, and we look forward to continuing to improve cancer care by expanding access to advanced molecular testing for the patients that we serve under the NeoGenomics banner moving forward.”